Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT04813406 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Start date: March 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of anlotinib combined with sindilimab as second-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In addition, we also explored the possible mechanism of anlotinib combined with sindilimab in order to screen out biomarkers that can predict the efficacy of the combination therapy.

NCT ID: NCT04797507 Not yet recruiting - Anlotinib Clinical Trials

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Start date: March 2021
Phase: Phase 2
Study type: Interventional

This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better therapy strategy for esophageal squamous cell cancer patients.

NCT ID: NCT04780750 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Concurent Chemoradiotherapy in Head and Neck Cancers

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for locally advanced HNSCC

NCT ID: NCT04716751 Not yet recruiting - Clinical trials for Tracheal Squamous Cell Carcinoma

Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab + carboplatin + paclitaxel in 15 newly diagnosed patients with tracheal malignant tumors.

NCT ID: NCT04678791 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Start date: December 2020
Phase: N/A
Study type: Interventional

To investigate the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of local advanced cervical squamous cell carcinoma.

NCT ID: NCT04654403 Not yet recruiting - Esophageal Cancer Clinical Trials

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab or Camrelizumab plus chemotherapy in patients with untreated, advanced ESCC with PD-L1 CPS≥10 ,who have been achieved PR and CR after treated with Camrelizumab.

NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04595981 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma

Chemo-embolization for Head and Neck Cancer

Start date: May 2025
Phase: Phase 2
Study type: Interventional

The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer patients with an acceptable morbidity rate.

NCT ID: NCT04533490 Not yet recruiting - Clinical trials for Resectable Esophageal Squamous Cell Carcinoma

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 for adjuvant treatment of resectable esophageal squamous cell carcinoma

NCT ID: NCT04533321 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Start date: September 2020
Phase: Phase 2
Study type: Interventional

Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy. There is also evidence of improvement of progression free survival of patients with metastatic/recurrent SCC of the head and neck after failure of chemotherapy in patients treated with afatinib. Therefore, treatment of patients with these 2 conditions with afatinib is not experimental, and will follow conventional clinical management.